Legend Biotech (LEGN) Liabilities and Shareholders Equity (2019 - 2025)

Legend Biotech (LEGN) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $1.7 billion in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 3.8% year-over-year to $1.7 billion; the TTM figure through Dec 2025 stood at $6.8 billion (down 3.25% YoY), while the FY2025 annual figure was $1.7 billion, up 3.8% from the prior year.
• Liabilities and Shareholders Equity grew to $1.7 billion in Q4 2025, from $1.7 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $615.3 billion in Q1 2021 and bottomed at $813.8 million in Q3 2021.
• A 5-year average of $35.6 billion and a median of $1.7 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The widest YoY moves for Liabilities and Shareholders Equity: up 55.03% in 2021, down 99.89% in 2021.
• Year by year, Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then climbed by 18.89% to $1.3 billion in 2022, then soared by 38.89% to $1.8 billion in 2023, then decreased by 9.65% to $1.7 billion in 2024, then increased by 3.8% to $1.7 billion in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $1.7 billion (Q4 2025), $1.7 billion (Q3 2025), and $1.7 billion (Q2 2025), per Business Quant data.

Peer Comparison